Introducing GPEx® Lightning: Next Gen Cell Line Engineering to Speed Your Path to Clinic
Summary: Speed and efficiency remain major drivers for developers bringing their protein-based biologics to first-in-human studies. For 20 years, GPEx® cell line development technology has provided a proven approach to generate high expressing, highly stable mammalian cell lines with 13 commercially approved biologics that have been developed to date. Building off the synergies of GPEx technology and a glutamine-synthetase knockout, Catalent introduces GPEx® Lightning, a fast, flexible way to shorten the path to production of phase 1 material. During this talk, we share the latest data leveraging GPEx Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials.